Treatment Efficacy of MEDI3902 in Pseudomonas aeruginosa Bloodstream Infection and Acute Pneumonia Rabbit Models

  • Antimicrob Agents Chemother. 2019 Jul 25;63(8):e00710-19. doi: 10.1128/AAC.00710-19.
Hoan N Le  #  1 ,  Vuvi G Tran  #  1 ,  Trang T T Vu  1 ,  Emmanuelle Gras  1  2 ,  Vien T M Le  1 ,  Marcos Gabriel Pinheiro  1  3 ,  Fábio Aguiar-Alves  1  3 ,  Erika Schneider-Smith  1 ,  Henry Clay Carter  1 ,  Bret R Sellman  4 ,  C Kendall Stover  4 ,  Antonio DiGiandomenico  5 ,  Binh An Diep  6
Affiliations
  • 1. Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA.
  • 2. François Rabelais University, Tours, France.
  • 3. Pathology Program, Fluminense Federal University, Rio de Janeiro, Brazil.
  • 4. Microbial Sciences, AstraZeneca, Gaithersburg, Maryland, USA.
  • 5. Microbial Sciences, AstraZeneca, Gaithersburg, Maryland, USA [email protected] [email protected].
  • 6. Division of HIV, Infectious Diseases, and Global Medicine, Department of Medicine, University of California, San Francisco, San Francisco, California, USA [email protected] [email protected].
  • # Contributed equally.
PMID: 31160288 DOI: 10.1128/AAC.00710-19
Abstract

Pseudomonas aeruginosa is a challenge for clinicians due to increasing drug resistance and dwindling treatment options. We report on the activity of MEDI3902, an antibody targeting type 3 secretion protein PcrV and Psl exopolysaccharide, in rabbit bloodstream and lung Infection models. MEDI3902 prophylaxis or treatment was protective in both acute models and exhibited enhanced activity when combined with a subtherapeutic dose of meropenem. These findings further support MEDI3902 for the prevention or treatment of serious P. aeruginosa infections.

Keywords
Pseudomonas aeruginosa; bloodstream infections; immunotherapy; pneumonia.
Products